Challenges in the Analysis of Micro RNAs from Liquid Biopsy as Epigenetic Biomarkers in Clinical Samples

José Luis García-Giménez1-5*, Gisselle Pérez-Machado4,5, Eva García-López5, Daymé González-Rodríguez5 and Salvador Mena-Mollá3-5*

1Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain

2INCLIVA Biomedical Research Institute, Valencia, Spain

3Department of Physiology, School of Medicine and Dentistry, Universitat de València (UV), Valencia, Spain

4Epigenetics Research Platform (CIBERER/ UV/INCLIVA), Valencia, Spain

5EpiDisease S.L. Spin-Off of CIBERER (ISCIII). Valencia, Spain

*Corresponding Authors:
José Luis García Giménez
Center for Biomedical Network Research on Rare Diseases (CIBERER)
Institute of Health Carlos III, Valencia, Spain.
E-mail: [email protected]
 
Salvador Mena Mollá, Ph.D
Department of Physiology, Faculty of Pharmacy
University of Valencia, Av/Vicente Andrés Estellés s/n, Burjassot
46100 Burjassot, Valencia, Spain.

Received date: December 19, 2017; Accepted date: December 20, 2017; Published date: December 22, 2017

Citation: Giménez JLG, Machado GP, López EG, Rodríguez DG, Mollá SM (2017) Challenges in the Analysis of Micro RNAs from Liquid Biopsy as Epigenetic Biomarkers in Clinical Samples. J Clin Epigenet. 3:47. doi: 10.21767/2472-1158.100081

 
Visit for more related articles at Journal of Clinical Epigenetics

Introduction

Advances in precision medicine, with better diagnostic and treatment strategies, are the hope to improve the management of diseases, comorbidities and mortality. For this purpose, biomarker research, especially based on liquid biopsies, has increased in recent years.

We recently defined an epigenetic biomarker as “any epigenetic mark or altered epigenetic mechanism” that can: (1) be measured in the body fluids or tissues; (2) detect a disease; (3) predict the outcome of a disease and future comorbidities (prognostic); (4) respond to therapy (predictive); (5) monitor responses to therapy or medication (therapy monitoring); and (6) predict risk of future disease development (risk). Therefore, miRNAs are potential biomarkers that fulfill most of these requirements.

In this context, epigenetic dysregulation and in particular microRNAs (miRNAs) play a central role in the initiation, progression and treatment response of human diseases because of their dynamic nature.

Advantages of miRNA Analysis in Liquid Biopsy

There are plenty of advantages of epigenetic biomarkers compared to genetic biomarkers, one of them being that the former provide vital information about gene function in individual cell types, and specific phenotypes [1,2]. For example, altered transcriptional profiles of miRNAs are a hallmark of several human diseases [3]. Such differential miRNA alterations have been taken advantage of to provide new biomarkers to improve clinical decisions in medicine.

It is worth mentioning that miRNAs are responsible for the finetuning of fundamental cellular activities and human disease development [4]. For this reason, miRNAs can fill clinical research gaps by incorporating new, relevant information regarding epigenetic control on specific genetic programs and, in turn, on the molecular pathways underlying pathological processes.

A relevant feature of miRNAs is their high stability in samples of compromised quality (e.g. thawed and FFPE tissues) [5], as well as the fact that they can be detected efficiently in a wide array of biospecimens (e.g. cells, fresh and frozen tissues, FFPE, etc.) [6]. They can also be detected in body fluids such as saliva, blood (plasma and serum), sputum, tears, breast milk, and cerebrospinal fluids [7,8].

Additionally, it has been demonstrated that miRNAs are stable in archived serum samples frozen at -25°C for at least 40 years [9] and at -20°C for at least 2-4 years [10]. Because of these properties, miRNAs hold great promise as minimally invasive diagnostic and prognostic biomarkers.

Challenges in the Analysis of miRNAs on Liquid Biopsy

Due to the intense research activity in this field, an increased number of miRNAs are being proposed as biomarkers but there is still a long way ahead to convert them into reliable tools for diagnosis and prognosis.

The detection of miRNA profiles in several biofluid samples poses a challenge in many ways. For example, biofluids contain very low amounts of RNA, and miRNAs are a small fraction of the total RNA. In addition, biofluids and the collector tubes used for sampling can contain inhibitors of enzymatic reactions (e.g. heparin) used in some detection methods, which could mask the subsequent detection of subtle changes in the miRNA expression profile.

Four critical factors can alter the interpretation of the results obtained after analyzing miRNAs: 1) the source of miRNA (cellular or extracellular origin); 2) the isolation/purification method; 3) the detection method and 4) the reference or normalization method used to interpret the results.

On the one hand, blood is one of the most common samples used in clinical research and diagnostics, possibly due to the fact that it is a readily available tissue and there are a lot of blood derivative samples stored in repositories or biobanks, making it easy to access. Furthermore, isolating miRNA from serum or plasma is relatively straightforward. The miRNAs detected in biological samples may be of cellular or extracellular origin [11], and both may be relevant in terms of biomarker discovery. On the other hand, sometimes the regulatory genetic mechanisms in which these miRNAs are involved have not been fully clarified.

Although miRNAs are highly expressed in blood cells, the level of plasmatic miRNA can be altered significantly by the various extents of hemolysis [12]. For this reason, hemolysis is one of the obstacles to overcome if the goal is to analyze the extracellular miRNA profile in biofluids, which are also susceptible to many pre-analytical variables. The clinical samples derived from pathological body fluids may contain not only sick cells but also large proportions of normal cells that can also release altered levels of the biomarker of interest, therefore complicating the interpretation of the results. Thus, when monitoring the levels of miRNAs in consecutive samples, e.g. during treatment monitoring, changes in miRNA signatures or levels could reflect a mere variation in the composition of the broken cell types within the samples instead of changes in the miRNA profile of the said biomarker. In addition, miRNAs can be released to the blood via a) exosomes, b) microvesicles, c) apoptotic bodies, d) high density lipoprotein (HDL) and e) AGO protein complex [13]. Therefore, when analyzing miRNAs, one must take into account which miRNA is to be isolated and in function of that, choose the appropriate method or kit for miRNA purification.

Nonetheless, there are many recommendations for overcoming these handicaps. For instance, it is usually advisable to use plasma samples rather than total blood samples and it is also better to choose a group of miRNA comprising an miRNA-signature, rather than only one miRNA. Preventing lysis of cells during all steps related to sample preparation is also recommended, preferably using EDTA and citrate as anticoagulants, since heparin can inhibit downstream enzymatic steps such as cDNA synthesis and PCR.

The miRNA isolation and purification steps are critical processes, and many aspects must be considered in order to make it feasible to use an miRNA as a biomarker. There are several protocols and commercial kits for miRNA purification that isolate free circulating miRNAs, protein-bound miRNAs, microvesicleassociated miRNAs or total miRNA from several biofluids such as serum/plasma, urine and others [14], but they still have certain limitations to overcome in order to successfully perform biomarker measurement.

Likewise, there are several platforms used for profiling miRNAs in biofluids based on NGS, arrays and RT-qPCR. NGS is the method of choice if the main goal is to discover novel miRNA sequences, or study isomiRNAs or miRNA editing. In turn, arrays offers the flexibility to perform miRNome analysis, while qPCR enables miRNA profiling and validation of a subset of miRNAs, and is well suited for accurate differential expression analysis of a defined set of miRNAs [15]. Besides those current technologies for miRNA analysis, various nanotechnology-based approaches are appearing, such as miRNA biosensors, which in the near future will revolutionize miRNA detection and quantitation [16].

Although miRNA detection methods are widely studied, data normalization is yet unresolved, and choosing the appropriate miRNA for data normalization of differentially expressed circulating miRNAs is of special relevance to accomplishing better results [17,18]. At the present time, the identification of universal miRNA normalizers for a wide array of human pathologies seems unlikely, although using algorithms for data normalization (e.g. NormFinder, GeNorm, CV score and DataAssist) may help with this issue [18]. Therefore, the strategy should be based on the adoption of standardized methods to select disease-specific miRNA normalizers in plasma samples. Fortunately, the development of new techniques that allow absolute quantitation, such as droplet digital PCR (ddPCR), will help. In fact, the adaptation of new technologies and methods to a clinical laboratory environment may ensure the adoption of epigenetic biomarkers into the diagnostic process.

Conclusions

Although great effort is being made to implement protocols for effective sampling of biofluids and to develop new techniques to ascertain miRNA profiles related to pathological conditions in such biofluids, only a low number of reliable epigenetic biomarkers are currently being considered by clinicians. However, with technological advances, panels of miRNAs could be robustly, routinely, accurately, and inexpensively profiled in near future, to provide detailed information for patient diagnosis, prognosis, stratification and treatment decision and monitoring. miRNA have emerged as diagnostic targets in precision medicine, so we consider that US Food and Drug Administration (FDA) will approve new tests, methods and procedures for miRNA-based diagnostic in the near future.

Reference

Select your language of interest to view the total content in your interested language

Viewing options

Post your comment

Share This Article

Recommended Conferences

Flyer image
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh